For research use only. Not for therapeutic Use.
Peptide T is an HIV entry inhibitor currently under clinical trials for the treatment of HIV-related neurological and constitutional symptoms.
| Catalog Number | I013415 |
| CAS Number | 106362-32-7 |
| Molecular Formula | C₃₅H₅₅N₉O₁₆ |
| Purity | ≥95% |
| Target | HIV Bradykinin Receptor |
| Solubility | DMSO |
| IUPAC Name | (2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoic acid |
| InChI | InChI=1S/C35H55N9O16/c1-13(36)28(52)40-22(12-45)31(55)41-25(15(3)47)33(57)43-26(16(4)48)34(58)42-24(14(2)46)32(56)39-21(11-23(37)51)29(53)38-20(10-18-6-8-19(50)9-7-18)30(54)44-27(17(5)49)35(59)60/h6-9,13-17,20-22,24-27,45-50H,10-12,36H2,1-5H3,(H2,37,51)(H,38,53)(H,39,56)(H,40,52)(H,41,55)(H,42,58)(H,43,57)(H,44,54)(H,59,60)/t13-,14-,15+,16+,17+,20-,21-,22-,24-,25-,26-,27-/m0/s1 |
| InChIKey | IWHCAJPPWOMXNW-GBJHXVHASA-N |
| SMILES | CC(C(C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CO)NC(=O)C(C)N)O |
| Reference | [1]. Ferreira LA, et al. Peptide T, a novel bradykinin potentiator isolated from Tityus serrulatus scorpion venom. Toxicon. 1993 Aug;31(8):941-7.<br>[2]. Heseltine PN, et al. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol. 1998 Jan;55(1):41-51.<br>[3]. Pert CB, et al. Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9254-8. |
